Hauser, T. http://orcid.org/0000-0001-7097-2815
,
Dornberger, V.
Malzahn, U.
Grebe, S. J.
Liu, D.
Störk, S.
Nauck, M.
Friedrich, N.
Dörr, M.
Wanner, C.
Krane, V.
Hammer, F.
,
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01KG1202)
E.N.D.I. – the European Nephrology and Dialysis Institute
Projekt DEAL
Article History
Received: 15 September 2020
Accepted: 25 January 2021
First Online: 5 February 2021
Compliance with ethical standards
:
: Tobias Hauser, Vivien Dornberger, Uwe Malzahn, Sören Grebe, Dan Liu, Matthias Nauck, Nele Friedrich, Marcus Dörr, Vera Krane and Fabian Hammer declared no conflicts of interest. Stefan Störk reported grants from the German Ministry for Education and Research, research grants from Bayer and Boehringer and speaker honoraria/consultation fees from Astra Zeneca, Bayer, Boehringer, Novartis, Pfizer, Sanofi, Servier, all outside the submitted work. Christoph Wanner received grant support and honoraria outside of the present trial from Boehringer-Ingelheim, Idorsia and Sanofi-Genzyme and honoraria from AstraZeneca, Bayer, Chiesi, FMC, GILEAD, GSK, Lilly, MSD and Vifor.
: The trial was registered at clinicaltrials.gov (NCT01691053; first posted Sep. 24, 2012) and approved by the Ethics-committee at the Medical Faculty of the University of Würzburg and performed according to the International Conference on Harmonisation Good Clinical Practice guidelines and the Declaration of Helsinki.
: All participants gave written informed consent before being enrolled in this trial.
: All co-authors gave their consent to publish this manuscript.